Dymag designs and manufactures lightweight carbon composite car and motorcycle wheels for vehicle Original Equipment Manufacturers (OEMs), racing and the aftermarket.

In April 2015, Dymag’s successful raise of £678,054 was used to create more than 200 new jobs as the company speeds towards its destination: becoming the primary supplier of carbon composite wheels for both the motorcycle and automotive industries.

Dymag overfunded to £499,998 via SyndicateRoom in September 2017.

The story

Dymag has been making high-performance wheels since the 1970s for many forms of motorsport, including Formula One, Indy Car, touring car, Paris-Dakar rally, MotoGP and Superbike.

The technology initially employed was die-cast magnesium which led to the company’s name: Dymag. As a result of changes in technology, the company was forced to look at alternatives in the 1990s. This led to the first attempts to commercially produce carbon composite motorcycle wheels, and in the 2000s, carbon composite auto wheels.

B0004318

Dymag believes it was 10 years ahead of competitors in developing this technology for cars and motorcycles, yet the liquidation of the company in 2009 resulted in Austrian company Carbotech acquiring the patent rights and tooling patterns associated with the original Dymag auto wheel.

When Dymag Group—incorporated as CSA Performance Wheels—was restarted under its current ownership and management, it was necessary to bring new technology to market: the Dymag BOXSTROM carbon composite hybrid wheel.

Dymag3

The likes of BMW and Ford are embracing the technology progressively as part of a drive to reduce weight in vehicles and meet ever-stricter emissions targets, while at the same time improving car handling and passenger ride.

Dymag is planning to use funds raised in September 2017 to further product development and expand its current production facility, as well as sales and marketing resources to drive growth.

Chris is an international industrialist and general manager with over 25 years’ experience and knowledge of Asia Pacific, having lived for 10 years in Japan and Singapore. A former managing director of Dymag Racing UK Ltd between 1994 and 1997, Chris rescued the company from receivership in 2010 through his company CSA International. Chris has held senior executive positions with ABB, Invensys APV (now SPX), Blue Circle Industries (now Lafarge) and Perkins Large Engines (now part of Caterpillar Inc.).

The lead investor

Boundary Capital focuses on SEIS and EIS-eligible investments in early-stage growth companies primarily in the technology space. Its team comprises experienced investors and entrepreneurs with a shared belief that early-stage businesses are much more likely to succeed if the right support is provided alongside capital.

Boundary’s approach is to actively drive growth in partnership with portfolio companies by appointing an experienced executive to the Board to provide advice, support and contacts – its unique ‘Venturer’ model. David Gee is a partner in Boundary Capital with over 25 years’ industrial and venture capital experience in a range of sectors including automotive, electronics IT and materials.

‘Dymag has a very entrepreneurial and experienced team that has already secured several OEM supply contracts as a result of its technology being able to meet the most demanding performance requirements, whilst offering important weight and design benefits.’

– Boundary Capital, lead investor

See current opportunities

Articheck

EIS
Software & Computer Services
Articheck is an SaaS company which create passports for works-of-art to accompany them on their travels. The company raised funds on SyndicateRoom in 2017.

Active

Trading status

£12,624

Average investment

£618,571

Total raised

Biotechspert

EIS
Healthcare
Biotechspert aims to facilitate access to world-leading technical, scientific and commercial expertise. The company raised finance on SyndicateRoom.

Active

Trading status

£7,147

Average investment

£236,099

Total raised

Redecol

EIS
Medtech
Redecol, a company developing an asthma monitoring device to address the need for a new lung function test, succesfully raised funds on SyndicateRoom.

Active

Trading status

£8,545

Average investment

£555,438

Total raised

Re-Vana Therapeutics

EIS
Pharmaceuticals & Biotechnology
Re-Vana Therapeutics is a life science spin-out from Queen’s University Belfast. The company raised £1,104,593 on SyndicateRoom in September 2017.

Active

Trading status

£19,725

Average investment

£1,104,593

Total raised

e-Patient Network

EIS
Healthcare
ePatient Network provides rare disease patients with up-to-date scientific information, community insights and medical research and connects them with clinical trial opportunities through its Raremark platform.

Active

Trading status

£12,087

Average investment

£470,374

Total raised

Dem DX

EIS
Healthcare
Dem Dx is a diagnostic support tool for medical professionals that augments clinical diagnoses. Read about the company's successful raise here.

Active

Trading status

£20,994

Average investment

£524,868

Total raised